The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A < em > Post Hoc < /em > Analysis of the SONAR Randomized Trial

CONCLUSIONS: Atrasentan reduced the relative risk of the primary kidney outcome consistently across baseline UACR and eGFR subgroups. The absolute risk reduction was greater among patients in the lowest eGFR and highest albuminuria category who were at highest baseline risk. Conversely, the relative and absolute risks of heart failure hospitalization were similar across baseline UACR and eGFR subgroups.Clinical Trial registry name and registration number: Study of Diabetic Nephropathy with Atrasentan (SONAR), NCT01858532.PMID:34853062 | DOI:10.2215/CJN.07340521

Source: Clinical Journal of the American Society of Nephrology : CJASN - December 2, 2021 Category: Urology & Nephrology Authors: Simke W Waijer Ron T Gansevoort George L Bakris Ricardo Correa-Rotter Fan-Fan Hou Donald E Kohan Dalane W Kitzman Hirofumi Makino John J V McMurray Vlado Perkovic Sheldon Tobe Hans-Henrik Parving Dick de Zeeuw Hiddo J L Heerspink Source Type: research